The FDA has tied sodium-glucose cotransporter-2 inhibitors to 55 cases of a life-threatening form of gangrene in the past six years, according to a May 7 report in the Annals of Internal Medicine.

Diabetic ketoacidosis is more prevalent in the U.S. than it is in Canada, according to a joint analysis from Harvard Medical School, the Cambridge Health Alliance, City University of New York and the University of Manitoba.

Researchers at the University of Georgia have uncovered 27 new metabolites associated with arterial stiffness, according to work published in the American Journal of Hypertension.

Vivimed Life Sciences on May 3 announced a voluntary recall of 19 lots of losartan potassium tablets, making it the third company in two weeks to issue a recall of the blood pressure (BP) drug.

A Harvard cardiologist and his team have developed an experimental genetic test for predicting obesity, NPR reports.

Long-term exposure to low doses of ionizing radiation raises a person’s risk for developing high blood pressure, according to a Hypertension study of more than 22,000 nuclear facility workers in Russia.

The latest drug company to issue a recall of losartan is Teva Pharmaceuticals, which on April 29 announced it was recalling 35 lots of the popular blood pressure medication.

Intensive therapy to keep blood pressure (BP) levels below 130/80 mmHg helped lower the risk for heart attacks, strokes and other CV complications in patients with concomitant type 2 diabetes and hypertension, researchers have found.